Test Preparation : No special preparation required

Sample : Slides

Methodlogy : IHC

Description :

WHAT IS IT?

To determine whether CD99 protein is present in tissue samples, pathologists utilise the Immunohistochemistry (IHC) CD99 test. In this test, particular antibodies that bind to the CD99 protein are used, and the binding is subsequently visible thanks to a staining procedure. Due to its importance in identifying specific tumour forms, most notably Ewing's sarcoma and other associated cancers, CD99 is of great interest. Pathologists can accurately diagnose and categorise tumours by using the IHC CD99 test on tissue sections to evaluate whether CD99 is expressed on the surface of cells in the sample. The test results provide doctors and oncologists with vital information that they can use to create effective treatment plans and give patients the best care possible. The IHC CD99 test is a prime example of immunohistochemistry's power in the field of molecular pathology. It improves our capacity to distinguish between distinct diseases and, as a result, results in better patient outcomes.

WHY?

A key tool in medical diagnosis is the Immunohistochemistry (IHC) CD99 test, which offers vital information on the make-up of tissue samples. It is particularly helpful in tumours like Ewing's sarcoma and primitive neuroectodermal tumours because it reveals the presence and distribution of CD99 protein within cells. For proper diagnosis and classification of cancers, CD99 expression patterns act as distinguishing markers. The test aids in the early diagnosis of disease, the classification of tumour types, and the selection of the most appropriate therapeutic strategies, making a substantial contribution to personalised medicine and enhancing oncology outcomes.

PRECAUTIONS

To ensure accurate findings, the Immunohistochemistry (IHC) CD99 test comprises multiple procedures. First, tissue samples are embedded in paraffin, preserved in a solution like formalin, and cut into thin sections. Blocking drugs are needed to stop nonspecific binding, and antigen retrieval is required to reveal the CD99 protein. A secondary antibody connected to a recognisable marker follows the first CD99 antibody in targeting the protein. Enzymatic reactions, colour changes, or fluorescence are used in the detecting process. Counterstaining can be used to make the cellular architecture more visible. A pathologist then examines the slides.